Rare Neurological Disease Treatment Market
Rare Neurological Disease Treatment Market By Drug Class (Anti-depressants, Anti-psychotics, Cholinesterase Inhibitors, Biologics), By Route of Administration (Injectable, Oral), By Disease Indication, By Distribution Channel & By Region - Global Market Insights 2018 to 2028
Analysis of Rare Neurological Disease Treatment Market Ccovering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Rare Neurological Disease Treatment Market Outlook
The global rare neurological disease treatment market is projected to expand at a stellar CAGR of over 8.5% and is anticipated to grow 2.3x between 2018 and 2028.
Over the last decade, the prevalence of rare diseases, evolving trend of orphan drugs and increasing expenditure on healthcare has provided a huge momentum to overall sales of rare neurological drugs.
As a result, the global sales within the rare neurological disorder treatment market has achieved a new milestone and surpassed the valuation of US$ 6.5 Bn in 2019.
In addition, due to their relatively high market value share and growth rate, the rare neurological disease treatment market is estimated to remain the most lucrative market within the rare disease treatment markets.
Furthermore, rapid developments in healthcare and dramatic socioeconomic changes resulting in modified lifestyles is also giving opportunities to manufacturers to expand their footprint within the rare neurological disease treatment market.
Don't Need a Global Report?
save 40%! on Country & Region specific reports
Revenue Share in Injectable Segment is forecast to Jump ~180 BPS
Ongoing research and development activities in the field of rare neurological disease treatment are proliferating on the back of increasing demand for orphan drugs.
This is anticipated to create an absolute dollar opportunity of US$ 8.1 Bn between 2018 and 2028.
The promulgation of disposable injectors is rapidly covering all aspects of the rare neurological disease treatment market. Hence, injectable drug delivery devices are acquiring a leading position.
Furthermore, increasing demand for patient friendly parenteral drug delivery systems and increasing number of surgical treatments are expected to boost the growth of injectable segment over the forecast period.
Biologics Segment to Account for over 40% Market Share in Drug Class Category
A biopharmaceutical revolution is showing its prevalence in pharmaceutical research and development laboratories which is driving industry-wide progress, including the advancement of primary packaging and delivery technologies.
Biologics is enabling the treatment of cancers, chronic autoimmune and lifestyle diseases that were previously untreatable. The biologics segment is projected to expand at a CAGR of over 7.5% over the long term forecast period (2018 to 2028).
The key players in the biologics segments are likely to face less competition across the globe on back of the high level of complexity that is associated with the production of biologics.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Asia-Pacific to Pave Way for Profitable Alliances for Key Manufacturers
North America is poised to be the leading region in the global rare neurological disease treatment market accounting for a 2/5th market share in 2019 on the back of well-established healthcare infrastructure and continuous emphasis on R&D in drugs and treatment of rare diseases.
Changing regional demographics, epidemiology and amplified healthcare coverage plans in regions such as South Asia, East Asia and Latin America are propelling the global rare neurological disease treatment market within these regions.
In Europe, the disease treatment industry is mainly bound to various government policies and market strategies.
In a bid to attain a competitive edge over the market players at the global platforms, the players in Europe are concentrating on offering product innovations.
Innovations in Value Chain is Setting a New Growth Trajectory for Key Market Actors
The global rare neurological disease treatment market is expected to showcase a consolidated market structure.
Key industry giants such as Novartis AG, Pfizer Inc., and Johnson & Johnson Services, Inc. hold more than 50% of share in the global rare neurological disease treatment market and are anticipated to attract more end users in near future owing to its brand positioning across the globe.
Manufacturers are focused on developing new therapies to decrease the burden of rare diseases, thus increasing their respective market shares.
In addition, innovations across the value chain and drug delivery models is likely to play a vital role in order to gain more penetration in the global market.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
Global Rare Neurological Disease Treatment Market: In-Depth Assessment on Key Segments
The global rare neurological disease treatment market is segmented on the basis of drug class, route of administration, disease indication, distribution channel, and region.
-
By Drug Class :
- Anti-depressants
- Anti-psychotics
- Cholinesterase Inhibitors
- Biologics
- Others (Anti-vertigo, Anti-seizure, etc.)
-
By Route of Administration :
- Injectable
- Oral
- By Disease Indication :
- Alzheimer's Diseases
- Narcolepsy
- Multiple Sclerosis
- Amyotrophic Lateral Sclerosis
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies and Drug Store
- Online Pharmacies
-
By Region :
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East & Africa
This taxonomy and the detailed TOC prepared are confidential and intended exclusively for the individual or entity with whom it is being shared.
Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.
Country-specific assessment on demand for rare neurological disease treatment has been provided for each regional market, along with the market size valuation and forecast price point assessment, price index and impact analysis of key regional and country-wise dynamics, which were obtained through quotes from numerous rare neurological disease treatment manufacturers, experts, and suppliers.
Y-o-Y growth projections have also been offered on all regional markets incorporated in the report. Moreover, future trends, growth prospects, and other possibilities related to the market have been answered in the report.
The report provides company-level market share analysis, which has been derived on the basis of the company’s annual sales and segmental revenue in all the target disease indications. The market has been forecasted based on constant currency rates.
The report provides detailed competitive and company profiles of key participants operating in the global rare neurological disease treatment market.
Some of the key competitors operating in the rare neurological disease treatment market are Novartis AG, Pfizer, Inc., Johnson & Johnson Services, Inc. Bayer AG, GlaxoSmithKline Plc, Sanofi S.A., Allergan Plc, Merck & Co., Inc., and others.
Table of Content
- 1. Global Market - Executive Summary
- 2. Global Market Overview
- 3. Key Market Trends
- 4. Key Success Factors
- 5. Global Pricing Point Analysis
- 6. Global Market Demand (in Value US$ Mn) Analysis 2013 to 2017 and Forecast 2018 to 2028
- 7. Market Background
- 8. Global Market Analysis 2013 to 2017 and Forecast 2018 to 2028, by Drug Class
- 8.1. Anti-depressants
- 8.2. Anti-psychotics
- 8.3. Cholinesterase Inhibitors
- 8.4. Biologics
- 8.5. Others (Anti-vertigo, anti-seizure)
- 9. Global Market Analysis 2013 to 2017 and Forecast 2018 to 2028, by Route of Administration
- 9.1. Injectable
- 9.2. Oral
- 10. Global Market Analysis 2013 to 2017 and Forecast 2018 to 2028, by Disease Indication
- 10.1. Alzheimer’s Disease
- 10.2. Narcolepsy
- 10.3. Multiple Sclerosis
- 10.4. Amyotrophic Lateral Sclerosis
- 10.5. Others
- 11. Global Market Analysis 2013 to 2017 and Forecast 2018 to 2028, by Distribution Channel
- 11.1. Hospitals Pharmacies
- 11.2. Retail Pharmacies & Drug Stores
- 11.3. Online Pharmacies
- 12. Global Market Analysis 2013 to 2017 and Forecast 2018 to 2028, by Region
- 12.1. North America
- 12.2. Latin America
- 12.3. Europe
- 12.4. South Asia
- 12.5. East Asia
- 12.6. Oceania
- 12.7. MEA
- 13. North America Market Value Analysis and Forecast 2013 to 2028
- 14. Latin America Market Value Analysis and Forecast 2013 to 2028
- 15. Europe Market Value Analysis and Forecast 2013 to 2028
- 16. South Asia & Oceania Market Value Analysis and Forecast 2013 to 2028
- 17. East Asia Market Value Analysis and Forecast 2013 to 2028
- 18. Oceania Market Value Analysis and Forecast 2013 to 2028
- 19. Middle East & Africa Market Value Analysis and Forecast 2013 to 2028
- 20. Global Market - Emerging Countries Analysis
- 21. Competitive Assessment
- 22. Company Profiles
- 22.1. Novartis AG
- 22.2. Pfizer, Inc.
- 22.3. Sanofi S.A.
- 22.4. Bayer AG
- 22.5. Merck & Co. Inc.
- 22.6. Allergan Plc
- 22.7. Johnson & Johnson Services, Inc.
- 22.8. Abbott Laboratories
- 22.9. GlaxoSmithKline Plc
- 22.10. Teva Pharmaceutical Industries Ltd.
- 22.11. Sun Pharmaceutical Industries Ltd
- 22.12. Biogen, Inc.
- 22.13. Eisai Co., Ltd.
- 22.14. Acer Therapeutics, Inc. (Opexa)
- 22.15. Wockhardt Limited
- 22.16. AB Science
- 23. Fact.MR Research Methodology
- 24. Disclaimer & Contact Information
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 1: Global Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 2: Global Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 3: Global Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 4: Global Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 5: Global Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 6: Global Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 7: Global Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 8: Global Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 9: Global Market Value (US$ Mn) Analysis and Forecast by Region, 2013 to 2017
Table 10: Global Market Value (US$ Mn) Analysis and Forecast by Region, 2018 to 2028
Table 11: North America Market Value (US$ Mn) Analysis and Forecast by Country, 2013 to 2017
Table 12: North America Market Value (US$ Mn) Analysis and Forecast by Country, 2018 to 2028
Table 13: North America Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 14: North America Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 15: North America Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 16: North America Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 17: North America Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 18: North America Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 19: North America Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 20: North America Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 21: Latin America Market Value (US$ Mn) Analysis and Forecast by Country, 2013 to 2017
Table 22: Latin America Market Value (US$ Mn) Analysis and Forecast by Country, 2018 to 2028
Table 23: Latin America Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 24: Latin America Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 25: Latin America Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 26: Latin America Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 27: Latin America Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 28: Latin America Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 29: Latin America Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 30: Latin America Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 31: Europe Market Value (US$ Mn) Analysis and Forecast by Country, 2013 to 2017
Table 32: Europe Market Value (US$ Mn) Analysis and Forecast by Country, 2018 to 2028
Table 33: Europe Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 34: Europe Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 35: Europe Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 36: Europe Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 37: Europe Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 38: Europe Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 39: Europe Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 40: Europe Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 41: South Asia Market Value (US$ Mn) Analysis and Forecast by Country, 2013 to 2017
Table 42: South Asia Market Value (US$ Mn) Analysis and Forecast by Country, 2018 to 2028
Table 43: South Asia Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 44: South Asia Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 45: South Asia Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 46: South Asia Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 47: South Asia Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 48: South Asia Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 49: South Asia Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 50: South Asia Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 51: East Asia Market Value (US$ Mn) Analysis and Forecast by Country, 2013 to 2017
Table 52: East Asia Market Value (US$ Mn) Analysis and Forecast by Country, 2018 to 2028
Table 53: East Asia Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 54: East Asia Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 55: East Asia Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 56: East Asia Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 57: East Asia Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 58: East Asia Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 59: East Asia Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 60: East Asia Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 61: Oceania Market Value (US$ Mn) Analysis and Forecast by Country, 2013 to 2017
Table 62: Oceania Market Value (US$ Mn) Analysis and Forecast by Country, 2018 to 2028
Table 63: Oceania Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 64: Oceania Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 65: Oceania Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 66: Oceania Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 67: Oceania Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 68: Oceania Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 69: Oceania Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 70: Oceania Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 71: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Country, 2013 to 2017
Table 72: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Country, 2018 to 2028
Table 73: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 74: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 75: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 76: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 77: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 78: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 79: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 80: Middle East & Africa Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 81: Brazil Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 82: Brazil Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 83: Brazil Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 84: Brazil Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 85: Brazil Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 86: Brazil Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 87: Brazil Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 88: Brazil Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 89: India Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 90: India Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 91: India Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 92: India Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 93: India Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 94: India Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 95: India Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 96: India Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
Table 97: China Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2013 to 2017
Table 98: China Market Value (US$ Mn) Analysis and Forecast by Drug Class, 2018 to 2028
Table 99: China Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2013 to 2017
Table 100: China Market Value (US$ Mn) Analysis and Forecast by Route of Administration, 2018 to 2028
Table 101: China Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2013 to 2017
Table 102: China Market Value (US$ Mn) Analysis and Forecast by Disease Indication, 2018 to 2028
Table 103: China Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2013 to 2017
Table 104: China Market Value (US$ Mn) Analysis and Forecast by Distribution Channel, 2018 to 2028
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
FIG. 01: Global Market Value (US$ Mn), 2013 to 2028
FIG. 02: Global Market Share and BPS Analysis by Drug Class- 2018 & 2028
FIG. 03: Global Market Y-o-Y Growth Projections by Drug Class, 2018 to 2028
FIG. 04: Global Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 05: Global Market Share and BPS Analysis by Route of Administration - 2018 & 2028
FIG. 06: Global Market Y-o-Y Growth Projections by Route of Administration, 2018 to 2028
FIG. 07: Global Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 08: Global Market Share and BPS Analysis by Disease Indication - 2018 & 2028
FIG. 09: Global Market Y-o-Y Growth Projections by Disease Indication, 2018 to 2028
FIG. 10: Global Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 11: Global Market Share and BPS Analysis by Distribution Channel - 2018 & 2028
FIG. 12: Global Market Y-o-Y Growth Projections by Distribution Channel, 2018 to 2028
FIG. 13: Global Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 14: Global Market Share and BPS Analysis by Region - 2018 & 2028
FIG. 15: Global Market Y-o-Y Growth Projections by Region, 2018 to 2028
FIG. 16: Global Market Attractiveness Index by Region, 2018 to 2028
FIG. 17: North America Market Value (US$ Mn), 2013 to 2028
FIG. 18: North America Market Share and BPS Analysis by Country - 2018 & 2028
FIG. 19: North America Market Y-o-Y Growth Projections by Country, 2018 to 2028
FIG. 20: North America Market Attractiveness Index by Country, 2018 to 2028
FIG. 21: US Market Absolute $ Opportunity, 2017 to 2028
FIG. 22: Canada Market Absolute $ Opportunity, 2017 to 2028
FIG. 23: North America Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 24: North America Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 25: North America Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 26: North America Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 27: North America Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 28: North America Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 29: North America Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 30: North America Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 31: Latin America Market Value (US$ Mn), 2013 to 2028
FIG. 32: Brazil Market Absolute $ Opportunity, 2017 to 2028
FIG. 33: Mexico Market Absolute $ Opportunity, 2017 to 2028
FIG. 34: Rest of Latin America Market Absolute $ Opportunity, 2017 to 2028
FIG. 35: Latin America Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 36: Latin America Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 37: Latin America Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 38: Latin America Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 39: Latin America Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 40: Latin America Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 41: Latin America Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 42: Latin America Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 43: Europe Market Value (US$ Mn), 2013 to 2028
FIG. 44: Europe Market Share and BPS Analysis by Country- 2018 & 2028
FIG. 45: Europe Market Y-o-Y Growth Projections by Country , 2018 to 2028
FIG. 46: Europe Market Attractiveness Index by Country, 2018 to 2028
FIG. 47: Germany Market Absolute $ Opportunity, 2017 to 2028
FIG. 48: France Market Absolute $ Opportunity, 2017 to 2028
FIG. 49: Italy Market Absolute $ Opportunity, 2017 to 2028
FIG. 50: Denmark Market Absolute $ Opportunity, 2017 to 2028
FIG. 51: UK Market Absolute $ Opportunity, 2017 to 2028
FIG. 52: Russia Market Absolute $ Opportunity, 2017 to 2028
FIG. 53: Spain Market Absolute $ Opportunity, 2017 to 2028
FIG. 54: Rest of Europe Market Absolute $ Opportunity, 2017 to 2028
FIG. 55: Europe Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 56: Europe Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 57: Europe Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 58: Europe Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 59: Europe Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 60: Europe Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 61: Europe Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 62: Europe Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 63: South Asia Market Value (US$ Mn), 2013 to 2028
FIG. 64: South Asia Market Share and BPS Analysis by Country - 2018 & 2028
FIG. 65: South Asia Market Y-o-Y Growth Projections by Country, 2018 to 2028
FIG. 66: South Asia Market Attractiveness Index by Country, 2018 to 2028
FIG. 67: India Market Absolute $ Opportunity, 2017 to 2028
FIG. 68: Indonesia Market Absolute $ Opportunity, 2017 to 2028
FIG. 69: Thailand Market Absolute $ Opportunity, 2018 to 2029
FIG. 70: Malaysia Market Absolute $ Opportunity, 2018 to 2029
FIG. 71: Rest of South Asia Market Absolute $ Opportunity, 2018 to 2029
FIG. 72: South Asia Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 73: South Asia Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 74: South Asia Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 75: South Asia Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 76: South Asia Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 77: South Asia Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 78: South Asia Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 79: South Asia Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 80: East Asia Market Value (US$ Mn), 2013 to 2028
FIG. 81: East Asia Market Share and BPS Analysis by Country - 2018 & 2028
FIG. 82: East Asia Market Y-o-Y Growth Projections by Country, 2018 to 2028
FIG. 83: East Asia Market Attractiveness Index by Country, 2018 to 2028
FIG. 84: China Market Absolute $ Opportunity, 2017 to 2028
FIG. 85: Japan Market Absolute $ Opportunity, 2017 to 2028
FIG. 86: South Korea Market Absolute $ Opportunity, 2017 to 2028
FIG. 87: East Asia Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 88: East Asia Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 89: East Asia Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 90: East Asia Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 91: East Asia Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 92: East Asia Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 93: East Asia Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 94: East Asia Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 95: Oceania Market Value (US$ Mn), 2013 to 2028
FIG. 96: Oceania Market Share and BPS Analysis by Country - 2018 & 2028
FIG. 97: Oceania Market Y-o-Y Growth Projections by Country, 2018 to 2028
FIG. 98: Oceania Market Attractiveness Index by Country, 2018 to 2028
FIG. 99: Australia Market Absolute $ Opportunity, 2017 to 2028
FIG. 100: New Zealand Market Absolute $ Opportunity, 2017 to 2028
FIG. 101: Oceania Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 102: Oceania Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 103: Oceania Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 104: Oceania Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 105: Oceania Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 106: Oceania Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 107: Oceania Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 108: Oceania Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 109: MEA Market Value (US$ Mn), 2013 to 2028
FIG. 110: MEA Market Share and BPS Analysis by Country- 2018 & 2028
FIG. 111: MEA Market Y-o-Y Growth Projections by Country , 2018 to 2028
FIG. 112: MEA Market Attractiveness Index by Country, 2018 to 2028
FIG. 113: GCC Countries Market Absolute $ Opportunity, 2017 to 2028
FIG. 114: Northern Africa Market Absolute $ Opportunity, 2017 to 2028
FIG. 115: South Africa Market Absolute $ Opportunity, 2017 to 2028
FIG. 116: Rest of MEA Market Absolute $ Opportunity, 2017 to 2028
FIG. 117: MEA Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 118: MEA Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 119: MEA Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 120: MEA Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 121: MEA Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 122: MEA Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 123: MEA Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 124: MEA Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 125: Global Vs. Country Y-o-Y Growth Projections, 2018 to 2028
FIG. 126: Brazil Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 127: Brazil Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 128: Brazil Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 129: Brazil Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 130: Brazil Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 131: Brazil Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 132: Brazil Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 133: Brazil Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 134: India Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 135: India Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 136: India Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 137: India Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 138: India Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 139: India Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 140: India Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 141: India Market Attractiveness Index by Distribution Channel, 2018 to 2028
FIG. 142: China Market Share and BPS Analysis by Drug Class - 2018 & 2028
FIG. 143: China Market Attractiveness Index by Drug Class, 2018 to 2028
FIG. 144: China Market Share and BPS Analysis by Route of Administration- 2018 & 2028
FIG. 145: China Market Attractiveness Index by Route of Administration, 2018 to 2028
FIG. 146: China Market Share and BPS Analysis by Disease Indication- 2018 & 2028
FIG. 147: China Market Attractiveness Index by Disease Indication, 2018 to 2028
FIG. 148: China Market Share and BPS Analysis by Distribution Channel- 2018 & 2028
FIG. 149: China Market Attractiveness Index by Distribution Channel, 2018 to 2028
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the CAGR for Rare Neurological Disease Treatment market?
The CAGR of over 8.5% Neurological Disease Treatment market
What are the segments covered in the Rare Neurological Disease Treatment report?
The global Location Intelligence market is segmented on the basis of basis of drug class, route of administration, disease indication, distribution channel, and region.
Rare Neurological Disease Treatment Market